BiomX Inc. (PHGE-UN)
USD 0.9
(-5.26%)
USD 0.9
(-5.26%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -1.22 Million USD | 53.73% |
| 2022 | -2.65 Million USD | -3.47% |
| 2021 | -2.56 Million USD | -17.66% |
| 2020 | -2.18 Million USD | -438.91% |
| 2019 | -404.52 Thousand USD | -92.63% |
| 2018 | -210 Thousand USD | -121.05% |
| 2017 | -95 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -317 Thousand USD | -6.02% |
| 2024 Q2 | -2.34 Million USD | -640.69% |
| 2023 Q4 | -299 Thousand USD | 2.92% |
| 2023 Q1 | -314 Thousand USD | 58.58% |
| 2023 FY | -1.22 Million USD | 53.73% |
| 2023 Q3 | -308 Thousand USD | -0.33% |
| 2023 Q2 | -307 Thousand USD | 2.23% |
| 2022 Q3 | -681 Thousand USD | -7.24% |
| 2022 FY | -2.65 Million USD | -3.47% |
| 2022 Q4 | -758 Thousand USD | -11.31% |
| 2022 Q2 | -635 Thousand USD | -0.47% |
| 2022 Q1 | -632 Thousand USD | 22.83% |
| 2021 Q2 | -566 Thousand USD | -1.98% |
| 2021 Q3 | -625 Thousand USD | -10.42% |
| 2021 Q4 | -819 Thousand USD | -31.04% |
| 2021 FY | -2.56 Million USD | -17.66% |
| 2021 Q1 | -555 Thousand USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 FY | -2.18 Million USD | -438.91% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2019 Q1 | -93.1 Thousand USD | -489.69% |
| 2019 Q4 | - USD | 100.0% |
| 2019 Q3 | -618.93 Thousand USD | -53.0% |
| 2019 FY | -404.52 Thousand USD | -92.63% |
| 2019 Q2 | -404.52 Thousand USD | -334.47% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q4 | -15.78 Thousand USD | 0.0% |
| 2018 FY | -210 Thousand USD | -121.05% |
| 2017 FY | -95 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 160 Thousand USD | 867.5% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | -391.2% |
| Armata Pharmaceuticals, Inc. | -29.24 Million USD | 95.8% |
| Actinium Pharmaceuticals, Inc. | -709 Thousand USD | -73.202% |
| Azitra, Inc. | 260.45 Thousand USD | 571.49% |
| Can-Fite BioPharma Ltd. | 743 Thousand USD | 265.276% |
| Chromocell Therapeutics Corporation | -2.57 Million USD | 52.392% |
| Calidi Biotherapeutics, Inc. | -1.25 Million USD | 2.229% |
| CEL-SCI Corporation | -3.95 Million USD | 68.977% |
| iBio, Inc. | -1.02 Million USD | -19.805% |
| Lineage Cell Therapeutics, Inc. | 8.27 Million USD | 114.842% |
| MAIA Biotechnology, Inc. | - USD | Infinity% |
| Matinas BioPharma Holdings, Inc. | -13.39 Million USD | 90.831% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | -929.381% |
| NovaBay Pharmaceuticals, Inc. | 7.89 Million USD | 115.554% |
| NanoViricides, Inc. | -759.01 Thousand USD | -61.789% |
| Oragenics, Inc. | -15.45 Million USD | 92.053% |
| BiomX Inc. | -1.22 Million USD | -0.0% |
| Protalix BioTherapeutics, Inc. | 42.51 Million USD | 102.889% |
| Palatin Technologies, Inc. | 4.39 Million USD | 127.957% |
| Scorpius Holdings, Inc. | -2.21 Million USD | 44.595% |